Publicacións en colaboración con investigadores/as de Hospital Universitari Germans Trias i Pujol (7)

2023

  1. Publisher Correction: Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (Nature Medicine, (2019), 25, 11, (1706-1714), 10.1038/s41591-019-0628-7)

    Nature Medicine

2022

  1. Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder

    European Urology, Vol. 82, Núm. 2, pp. 212-222

2021

  1. Epithelial-to-mesenchymal transition mediates resistance to maintenance therapy with vinflunine in advanced urothelial cell carcinoma

    Cancers, Vol. 13, Núm. 24

2018

  1. Pazopanib: Evidence review and clinical practice in the management of advanced renal cell carcinoma

    BMC Pharmacology and Toxicology, Vol. 19, Núm. 1

2017

  1. Maintenance therapy with vinflunine plus best supportive care versus best supportive care alone in patients with advanced urothelial carcinoma with a response after first-line chemotherapy (MAJA; SOGUG 2011/02): a multicentre, randomised, controlled, open-label, phase 2 trial

    The Lancet Oncology, Vol. 18, Núm. 5, pp. 672-681

2016

  1. Randomized placebo controlled phase II trial (MAJA): Efficacy results of maintenance vinflunine after cisplatin chemotherapy (CT) in patients with advanced urothelial carcinoma (UC). SOGUG 2011-02

    Annals of Oncology, Vol. 27, pp. vi277

  2. The Wide Experience of the Sequential Therapy for Patients with Metastatic Renal Cell Carcinoma

    Current Oncology Reports, Vol. 18, Núm. 11